These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 24273174)

  • 1. Evaluation of a human BCG challenge model to assess antimycobacterial immunity induced by BCG and a candidate tuberculosis vaccine, MVA85A, alone and in combination.
    Harris SA; Meyer J; Satti I; Marsay L; Poulton ID; Tanner R; Minassian AM; Fletcher HA; McShane H
    J Infect Dis; 2014 Apr; 209(8):1259-68. PubMed ID: 24273174
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimization of a Human Bacille Calmette-Guérin Challenge Model: A Tool to Evaluate Antimycobacterial Immunity.
    Minhinnick A; Harris S; Wilkie M; Peter J; Stockdale L; Manjaly-Thomas ZR; Vermaak S; Satti I; Moss P; McShane H
    J Infect Dis; 2016 Mar; 213(5):824-30. PubMed ID: 26450421
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A human challenge model for Mycobacterium tuberculosis using Mycobacterium bovis bacille Calmette-Guerin.
    Minassian AM; Satti I; Poulton ID; Meyer J; Hill AV; McShane H
    J Infect Dis; 2012 Apr; 205(7):1035-42. PubMed ID: 22396610
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A first-in-human phase 1 trial to evaluate the safety and immunogenicity of the candidate tuberculosis vaccine MVA85A-IMX313, administered to BCG-vaccinated adults.
    Minhinnick A; Satti I; Harris S; Wilkie M; Sheehan S; Stockdale L; Manjaly Thomas ZR; Lopez-Ramon R; Poulton I; Lawrie A; Vermaak S; Le Vert A; Del Campo J; Hill F; Moss P; McShane H
    Vaccine; 2016 Mar; 34(11):1412-21. PubMed ID: 26854906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The candidate TB vaccine, MVA85A, induces highly durable Th1 responses.
    Tameris M; Geldenhuys H; Luabeya AK; Smit E; Hughes JE; Vermaak S; Hanekom WA; Hatherill M; Mahomed H; McShane H; Scriba TJ
    PLoS One; 2014; 9(2):e87340. PubMed ID: 24498312
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dose-finding study of the novel tuberculosis vaccine, MVA85A, in healthy BCG-vaccinated infants.
    Scriba TJ; Tameris M; Mansoor N; Smit E; van der Merwe L; Mauff K; Hughes EJ; Moyo S; Brittain N; Lawrie A; Mulenga H; de Kock M; Gelderbloem S; Veldsman A; Hatherill M; Geldenhuys H; Hill AV; Hussey GD; Mahomed H; Hanekom WA; McShane H
    J Infect Dis; 2011 Jun; 203(12):1832-43. PubMed ID: 21606542
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial.
    Tameris MD; Hatherill M; Landry BS; Scriba TJ; Snowden MA; Lockhart S; Shea JE; McClain JB; Hussey GD; Hanekom WA; Mahomed H; McShane H;
    Lancet; 2013 Mar; 381(9871):1021-8. PubMed ID: 23391465
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serum indoleamine 2,3-dioxygenase activity is associated with reduced immunogenicity following vaccination with MVA85A.
    Tanner R; Kakalacheva K; Miller E; Pathan AA; Chalk R; Sander CR; Scriba T; Tameris M; Hawkridge T; Mahomed H; Hussey G; Hanekom W; Checkley A; McShane H; Fletcher HA
    BMC Infect Dis; 2014 Dec; 14():660. PubMed ID: 25466778
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial.
    Satti I; Meyer J; Harris SA; Manjaly Thomas ZR; Griffiths K; Antrobus RD; Rowland R; Ramon RL; Smith M; Sheehan S; Bettinson H; McShane H
    Lancet Infect Dis; 2014 Oct; 14(10):939-46. PubMed ID: 25151225
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety and Immunogenicity of Newborn MVA85A Vaccination and Selective, Delayed Bacille Calmette-Guerin for Infants of Human Immunodeficiency Virus-Infected Mothers: A Phase 2 Randomized, Controlled Trial.
    Nemes E; Hesseling AC; Tameris M; Mauff K; Downing K; Mulenga H; Rose P; van der Zalm M; Mbaba S; Van As D; Hanekom WA; Walzl G; Scriba TJ; McShane H; Hatherill M;
    Clin Infect Dis; 2018 Feb; 66(4):554-563. PubMed ID: 29028973
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A DNA vaccine expressing CFP21 and MPT64 fusion protein enhances BCG-induced protective immunity against Mycobacterium tuberculosis infection in mice.
    Wang C; Chen Z; Fu R; Zhang Y; Chen L; Huang L; Li J; Shi C; Fan X
    Med Microbiol Immunol; 2011 Aug; 200(3):165-75. PubMed ID: 21340709
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.
    Hawkridge T; Scriba TJ; Gelderbloem S; Smit E; Tameris M; Moyo S; Lang T; Veldsman A; Hatherill M; Merwe Lv; Fletcher HA; Mahomed H; Hill AV; Hanekom WA; Hussey GD; McShane H
    J Infect Dis; 2008 Aug; 198(4):544-52. PubMed ID: 18582195
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety and immunogenicity of an FP9-vectored candidate tuberculosis vaccine (FP85A), alone and with candidate vaccine MVA85A in BCG-vaccinated healthy adults: a phase I clinical trial.
    Rowland R; Pathan AA; Satti I; Poulton ID; Matsumiya MM; Whittaker M; Minassian AM; O'Hara GA; Hamill M; Scott JT; Harris SA; Poyntz HC; Bateman C; Meyer J; Williams N; Gilbert SC; Lawrie AM; Hill AV; McShane H
    Hum Vaccin Immunother; 2013 Jan; 9(1):50-62. PubMed ID: 23143773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans.
    McShane H; Pathan AA; Sander CR; Keating SM; Gilbert SC; Huygen K; Fletcher HA; Hill AV
    Nat Med; 2004 Nov; 10(11):1240-4. PubMed ID: 15502839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immunogenicity of the tuberculosis vaccine MVA85A is reduced by coadministration with EPI vaccines in a randomized controlled trial in Gambian infants.
    Ota MO; Odutola AA; Owiafe PK; Donkor S; Owolabi OA; Brittain NJ; Williams N; Rowland-Jones S; Hill AV; Adegbola RA; McShane H
    Sci Transl Med; 2011 Jun; 3(88):88ra56. PubMed ID: 21697532
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Novel vaccines against M. tuberculosis].
    Okada M
    Kekkaku; 2006 Dec; 81(12):745-51. PubMed ID: 17240920
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical development of an in vivo BCG challenge model for testing candidate TB vaccine efficacy.
    Minassian AM; Ronan EO; Poyntz H; Hill AV; McShane H
    PLoS One; 2011; 6(5):e19840. PubMed ID: 21629699
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Phase I, Open-Label Trial, Evaluating the Safety and Immunogenicity of Candidate Tuberculosis Vaccines AERAS-402 and MVA85A, Administered by Prime-Boost Regime in BCG-Vaccinated Healthy Adults.
    Sheehan S; Harris SA; Satti I; Hokey DA; Dheenadhayalan V; Stockdale L; Manjaly Thomas ZR; Minhinnick A; Wilkie M; Vermaak S; Meyer J; O'Shea MK; Pau MG; Versteege I; Douoguih M; Hendriks J; Sadoff J; Landry B; Moss P; McShane H
    PLoS One; 2015; 10(11):e0141687. PubMed ID: 26529238
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of vaccine dose on the safety and immunogenicity of a candidate TB vaccine, MVA85A, in BCG vaccinated UK adults.
    Pathan AA; Minassian AM; Sander CR; Rowland R; Porter DW; Poulton ID; Hill AV; Fletcher HA; McShane H
    Vaccine; 2012 Aug; 30(38):5616-24. PubMed ID: 22789508
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Protection against bovine tuberculosis induced by oral vaccination of cattle with Mycobacterium bovis BCG is not enhanced by co-administration of mycobacterial protein vaccines.
    Wedlock DN; Aldwell FE; Vordermeier HM; Hewinson RG; Buddle BM
    Vet Immunol Immunopathol; 2011 Dec; 144(3-4):220-7. PubMed ID: 22005585
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.